Brief: Argenx: $737 Million In Q4 Global Product Net Sales
27/02/2025 06:14
Feb 27 (Reuters) - argenx SE ARGX.BR: $737 MILLION IN Q4 AND $2.2 BILLION IN FULL YEAR GLOBAL PRODUCT NET SALES ARGENX EXPECTS ITS COMBINED RESEARCH AND DEVELOPMENT AND SELLING, GENERAL AND ADMINISTRATIVE EXPENSES IN 2025 TO BE APPROXIMATELY $2.5 BILLION PROFIT FOR THE PERIOD OF THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024 WAS $774 MILLION AND $833 MILLION, RESPECTIVELY Q4 OPERATING INCOME USD 103.0 MILLION Source text: ID:nGNE9NyCZ9 Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles